[ * ] = CERTAINCONFIDENTIALINFORMATIONCONTAINEDINTHISDOCUMENT,MARKEDBYBRACKETS,HASBEENOMITTEDANDFILEDSEPARATELYWITHTHE SECURITIESAND EXCHANGE COMMISSIONPURSUANTTO RULE 24B-2OFTHE SECURITIES EXCHANGE ACTOF 1934,ASAMENDED.
Exhibit 10.47
May 16, 2005
Richard B. Hollis
Hollis-Eden Pharmaceuticals, Inc.
4345 Eastgate Mall, Suite 400
San Diego, CA 92121
Dear Mr. Hollis:
The purpose of this letter agreement (Amendment 6) is to amend further the contract dated June 18, 2003. By signing below, the undersigned parties hereby agree to amend[ * ] of Exhibit B and replace them with[ * ]as reflected below:
[ * ]
| Total | $ | 1,700,000 | |||
[ * ]
Page 1
[ * ] = CERTAINCONFIDENTIALINFORMATIONCONTAINEDINTHISDOCUMENT,MARKEDBYBRACKETS,HASBEENOMITTEDANDFILEDSEPARATELYWITHTHE SECURITIESAND EXCHANGE COMMISSIONPURSUANTTO RULE 24B-2OFTHE SECURITIES EXCHANGE ACTOF 1934,ASAMENDED.
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | ||||||||
By: | /s/ R. Beall | /s/ P. Campbell | ||||||
Robert J. Beall, Ph.D. President and CEO | Preston W. Campbell, III, M.D. Executive Vice President of Medical Affairs | |||||||
| HOLLIS-EDEN PHARMACEUTICALS, INC. | ||||||||
By: | /s/ Richard B. Hollis | |||||||
Richard B. Hollis President | ||||||||
Page 2